Fundraising Fox
ADARx Pharmaceuticals
San Diego, US · Founded 2019 · 100 employees on LinkedIn · 10 known investors
Find your way into ADARx Pharmaceuticals
269 people in our graph share verified history with the ADARx Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Con McGrathunlockedknows Rob Ackles · together at Maritz (overlapped)
×3knows the team · via Ionis Pharmaceuticals, Inc.
knows the team · via Acadia Pharmaceuticals
×5knows the team · via Albemarle
knows the team · via Codexis
knows the team · via Maritz
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.
Founders & leadership
ADARx Pharmaceuticals was founded in 2019 by Zhen Li and Rui Zhu.
RZ
Rui ZhuFounding Member & Chief Technology Officer
RA
Rob AcklesChief People OfficerRob Ackles has served as Chief Human Resources Officer at multiple biotech companies over more than a decade, spanning startup through large-scale expansion phases. He brings nearly three decades of biopharmaceutical leadership experience in talent acquisition, organizational design, compliance, and workforce planning.
RF
RA
Robert A. MacLeodChief Scientific OfficerRobert A. MacLeod is Chief Scientific Officer of Adarx, a clinical-stage biotechnology company developing RNA-targeted therapeutics. He previously held research leadership roles at AstraZeneca and MD Anderson Cancer Center, where he directed drug discovery efforts across oncology, immunology, and genetic disease with expertise in RNA therapeutics and small molecule drug discovery.
CC
Christopher ClaeboeSenior Vice President of OperationsChristopher Claeboe holds a Ph.D. in Chemistry with a focus on bioorganic synthesis from the University of Virginia and an M.B.A. from Indiana University's Kelley School of Business. He serves as Senior Vice President of Operations at ADARx, a clinical-stage biotechnology company developing RNA-targeted therapeutics, and brings expertise in process scale-up, organic synthesis, and outsourcing management.
EC
Erez ChimovitsNamed on SEC filing
CG
Carl GordonNamed on SEC filing
HL
Hongbo LuNamed on SEC filing
Investors · 10
Bain Capital Life Sciences✓ confirmed by ADARx PharmaceuticalsBoston
How we know: the company's own site · Bain Capital Life Sciences's portfolio page · Not right? Tell us
OrbiMed✓ confirmed by ADARx PharmaceuticalsNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the company's own site · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
SR One Capital Management✓ confirmed by ADARx PharmaceuticalsRedwood City
How we know: SR One Capital Management's portfolio page · the company's own site · a partner's Signal profile · Not right? Tell us
Lilly Asia Ventures✓ confirmed by ADARx PharmaceuticalsHong Kong
How we know: the company's own site · board seat on SEC Form D · Not right? Tell us
T. Rowe Price✓ confirmed by ADARx PharmaceuticalsBaltimore
How we know: the company's own site · Not right? Tell us
Ascenta Capitallisted by Ascenta CapitalWilmington · $15M – $30M
How we know: Ascenta Capital's portfolio page · board seat on SEC Form D · Not right? Tell us
TCG Crossoverlisted by TCG CrossoverPalo Alto
How we know: board seat on SEC Form D · Not right? Tell us
Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M
How we know: Vivo Capital's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$352.5M disclosed across 7 rounds · 2020–2023
▶$200MraisedAug 2023 · 28 investors · BiotechnologyRule 506(b)
▶$200MraisedAug 2023 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rui ZhuExecutive Officer
- Simeon GeorgeDirector
- Judith LiDirector
- Erez ChimovitsDirector
- Sheila GujrathiDirector
- Zhen LiExecutive Officer, Director, Promoter
- Yuan (Eliza) SunDirector
- Chen YuDirector
- Ricky SunDirector
- Lorence KimDirector
- Carl GordonDirector
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$46MraisedJan 2023 · 10 investors · PharmaceuticalsRule 506(b)
▶$46MraisedJan 2023 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sheila GujrathiDirector
- Lorence KimDirector
- Judith LiDirector
- Zhen LiExecutive Officer, Director
- Erez ChimovitsDirector
- Simeon GeorgeDirector
- Rui ZhuExecutive Officer
- Yuan (Eliza) SunDirector
- Carl GordonDirector
- Offering amount
- $46M
- Amount sold
- $46M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$75MraisedAug 2021 · 6 investors · PharmaceuticalsRule 506(b)
▶$75MraisedAug 2021 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Xiong ZhangDirector
- Rui ZhuExecutive Officer
- Yuan SunDirector
- Sheila GujrathiDirector
- Simeon GeorgeDirector
- Zhen LiExecutive Officer, Director
- Erez ChimovitsDirector
- Carl GordonDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$15.5MraisedMay 2021 · 3 investors · PharmaceuticalsRule 506(b)
▶$15.5MraisedMay 2021 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carl GordonDirector
- Xiong ZhangDirector
- Zhen LiExecutive Officer, Director
- Sheila GujrathiDirector
- Rui ZhuExecutive Officer
- Erez ChimovitsDirector
- Offering amount
- $15.5M
- Amount sold
- $15.5M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6MraisedNov 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$6MraisedNov 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Zhen LiExecutive Officer, Director
- Rui ZhuExecutive Officer
- Carl GordonDirector
- Hongbo LuDirector
- Erez ChimovitsDirector
- Sheila GujrathiDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5MraisedAug 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$5MraisedAug 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Zhen LiExecutive Officer, Director
- Erez ChimovitsDirector
- Rui ZhuExecutive Officer
- Carl GordonDirector
- Hongbo LuDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5MraisedFeb 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$5MraisedFeb 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Zhen LiExecutive Officer, Director
- Rui ZhuExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does ADARx Pharmaceuticals do?
- ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.
- Who founded ADARx Pharmaceuticals?
- ADARx Pharmaceuticals was founded by Zhen Li, Rui Zhu in 2019.
- Who are ADARx Pharmaceuticals's investors?
- ADARx Pharmaceuticals's investors include Bain Capital Life Sciences, OrbiMed, SR One Capital Management, Lilly Asia Ventures, T. Rowe Price, Ascenta Capital, TCG Crossover, Vivo Capital and 2 more.
- How much funding has ADARx Pharmaceuticals raised?
- ADARx Pharmaceuticals has disclosed $352.5M raised across 7 rounds.
- Where is ADARx Pharmaceuticals headquartered?
- ADARx Pharmaceuticals is headquartered in San Diego, US.